Future strategies in treatment of parkinson’s disease

Authors

  • KH Janbaz Department of Pharmacy, Bahauddin Zakariya University, Multan,
  • MI Qadir College of Pharmacy, Government College University, Faisalabad,
  • F Younas Institute of Biotechnology, Bahauddin Zakariya University, Multan,
  • SA Malik Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad,

DOI:

https://doi.org/10.3126/jcmsn.v7i2.6687

Keywords:

Parkinson’s disease, levodopa, gene therapy

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder. COMT inhibitors, MOA-B inhibitors, Levodopa, Levodopa in combination with Dopa Decarboxylase (DDC) inhibitors, Entacapone, Tolcapone, Pramipexole, Ropinirole, Zonisamide, Cholinesterase inhibitors such as rivastigmine, galantamine and donepezil are used for treatment of Parkinson’s disease. Gene therapy of cellular and brain circuit pathways for the treatment of PD is under trials. Recently nuclear transfer embryonic stem cells or induced pluripotent stem derived cells can be used. The presence of Lewy bodies, reduced dopamine transporter and tyrosine hydroxylase expression within transplanted cells indicated that grafted cells are pathological. Adult and fetal neural stem cells are self-renewable.

Journal of College of Medical Sciences-Nepal, 2011, Vol-7, No-2, 67-71

DOI: http://dx.doi.org/10.3126/jcmsn.v7i2.6687

Downloads

Download data is not yet available.
Abstract
994
PDF
981

Downloads

Published

2012-08-23

How to Cite

Janbaz, K., Qadir, M., Younas, F., & Malik, S. (2012). Future strategies in treatment of parkinson’s disease. Journal of College of Medical Sciences-Nepal, 7(2), 67–71. https://doi.org/10.3126/jcmsn.v7i2.6687

Issue

Vol. 7 No. 2 (2011)

Section

Review Articles

License

This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.